top of page

Richard Zhao

Research Assistant

Notable Publications:

Zhang, J.*, Zhao, T., Jakobsson, V., Chen, X.* (2023). Clinical translation of radiotheranostics for precision oncology. Nat Rev Bioeng 1, 612–614 (2023).

Tan Y#, Li J#, Zhao T, Zhou M, Liu K, Xiang S, Tang Y, Jakobsson V, Xu P, Chen X, Zhang J. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. Eur J Nucl Med Mol Imaging. 2024 Apr 2. doi: 10.1007/s00259-024-06703-z. Epub ahead of print. PMID: 38561515. (IF = 9.1)

Baum, R. P.#, Wang, P.#, Jakobsson, V., Zhao, T., Schuchardt, C., Khong, P.-L., & Zhang, J.* (2024). Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics, 14(1), 133-142. (IF = 12.4)

Fu, H.#, Huang, J.#, Zhao, T.#, Wang, H., Chen, Y., Xu, W., Pang, Y., Guo, W., Sun, L., Wu, H., Xu, P., Su, B., Zhang, J.*, Chen, X.*, & Chen, H.* (2023). Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study. Clin Cancer Res, 29(23), 4740-4750. (IF = 11.5)

Liu, Q., Kulkarni, H. R., Zhao, T., Schuchardt, C., Chen, X., Zhu, Z.*, Zhang, J.*, & Baum, R. P.* (2023). Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors. Clin Nucl Med, 48(3), 221-227. (IF = 10.6)

Chen X, Zhang Z, Wang L, Zhang J, Zhao T, Cai J, Dang Y, Guo R, Liu R, Zhou Y, Wei R, Lou X, Xia F, Ma D, Li F, Dai J, Li F, Xi L. Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients. Eur J Nucl Med Mol Imaging. 2024 Feb 27. doi: 10.1007/s00259-024-06661-6. Epub ahead of print. PMID: 38411667. (IF=9.1)

Wang, R., Jakobsson, V., Wang, J., Zhao, T., Peng, X., Li, B., Xue, J., Liang, N.*, Zhu, Z.*, Chen, X.*, & Zhang, J.* (2023). Dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics, 13(9), 2979-2992. (IF = 12.4)

Wen, X.#, Xu, P.#, Zeng, X.#, Liu, J., Du, C., Zeng, X., Cheng, X., Wang, X., Liang, Y., Zhao, T., Yang, H., Li, H., Meng, L., Fang, J., Liu, H., Zhou, Z., Zhang, J.*, Zhang, X.*, Guo, Z.*, & Chen, X.* (2023). Development of [(177)Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging, 50(9), 2846-2860. (IF = 9.1)

Zang, J.#, Lin, R.#, Wen, X.#, Wang, C., Zhao, T., Jakobsson, V., Yang, Y., Wu, X., Guo, Z., Chen, X.*, Zhang, J.*, & Miao, W.* (2023). A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers. Clin Nucl Med, 48(10), 861-868. (IF = 10.6)

Zang, J.#, Wang, G.#, Zhao, T.#, Liu, H.#, Lin, X., Yang, Y., Shao, Z., Wang, C., Chen, H., Chen, Y., Zhu, Z.*, Miao, W.*, Chen, X.*, & Zhang, J.* (2023). A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [(177)Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. (IF = 9.1)

Liu N#, Wan Q#, Wu X, Zhao T, Jakobsson V, Yuan H, Chen X, Zhang J, Zhang W. A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1685-1697. doi: 10.1007/s00259-023-06587-5. Epub 2024 Jan 22. PMID: 38246909. (IF = 9.1)

Du, Z., Zhao, T., Chen, X., Zha, S., Wang, S.* (2024). A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells. In: Siciliano, V., Ceroni, F. (eds) Cancer Immunotherapy. Methods in Molecular Biology, vol 2748. (IF = 1.4)

Richard Zhao
bottom of page